Short answer
GERON CORP (GERN) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Geron issued a Phase 3 IMpactMF trial update for imetelstat in JAK inhibitor relapsed/refractory myelofibrosis.
GERON CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Geron issued a Phase 3 IMpactMF trial update for imetelstat in JAK inhibitor relapsed/refractory myelofibrosis
- Clinical update may materially affect imetelstat approval prospects, development timelines, and Geron’s valuation
- Full trial details and company commentary appear in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 IMpactMF discontinued after independent DMC judged overall-survival endpoint unlikely to be met
- Trial enrolled 327 relapsed/refractory myelofibrosis patients after JAK-inhibitor treatment
- No new safety signals, preserving imetelstat’s known safety profile but eliminating a major development opportunity
- Near-term strategy shifts toward growing U.S. RYTELO demand and expanding access for eligible LR-MDS patients
- Detailed efficacy and safety analyses pending, with findings planned for future scientific disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GERON CORP 8-K filings
Get the next GERN 8-K as it lands
Follow GERN for push alerts, or ask the research agent what this filing means.